These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 4223765)

  • 21. Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation.
    Sahni A; Baker CA; Sporn LA; Francis CW
    Thromb Haemost; 2000 May; 83(5):736-41. PubMed ID: 10823272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibrinogen-fibrin degradation products.
    Kwaan HC
    Ann Clin Lab Sci; 1980; 10(3):234-7. PubMed ID: 7396389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin.
    Doolittle RF; Pandi L
    Biochemistry; 2006 Feb; 45(8):2657-67. PubMed ID: 16489759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Analysis, by immuno-chemical methods, of the degradation by plasmin of human fibrinogen and fibrin, at different stages].
    NUSSENZWEIG V; SELIGMANN M
    Nouv Rev Fr Hematol; 1960; 15():451-66. PubMed ID: 13729935
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of fibrin and alpha2-antiplasmin on plasminogen activation by staphylokinase.
    Okada K; Ueshima S; Takaishi T; Yuasa H; Fukao H; Matsuo O
    Am J Hematol; 1996 Nov; 53(3):151-7. PubMed ID: 8895684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isolation of vasoactive peptides from human fibrin and fibrinogen degraded by plasmin.
    Belew M; Gerdin B; Porath J; Saldeen T
    Thromb Res; 1978 Dec; 13(6):983-94. PubMed ID: 155325
    [No Abstract]   [Full Text] [Related]  

  • 27. Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test.
    Hawiger J; Niewiarowski S; Gurewich V; Thomas DP
    J Lab Clin Med; 1970 Jan; 75(1):93-108. PubMed ID: 4243578
    [No Abstract]   [Full Text] [Related]  

  • 28. Action of fibrinolysin (plasmin) on proteins.
    KAPLAN EH
    Proc Soc Exp Biol Med; 1954 Jan; 85(1):142-4. PubMed ID: 13134315
    [No Abstract]   [Full Text] [Related]  

  • 29. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A.
    Pfitzner SA; Dempfle CE; Matsuda M; Heene DL
    Thromb Haemost; 1997 Sep; 78(3):1069-78. PubMed ID: 9308756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteolytic degradation products from fibrinogen and fibrin with special respect to non-covalently associated complexes. Influence of fibrin crosslinking. Lysability and other properties.
    Feddersen C
    Scand J Clin Lab Invest Suppl; 1983; 166():1-60. PubMed ID: 6226084
    [No Abstract]   [Full Text] [Related]  

  • 31. Differential degradation by plasmin of fragment E derived from fibrin and fibrinogen.
    Wallin R; Belew M; Gerdin B; Saldeen T
    Thromb Res; 1980 Aug; 19(3):441-5. PubMed ID: 6449096
    [No Abstract]   [Full Text] [Related]  

  • 32. [On the similarity of activity of thrombin and papaine in the reaction with fibrinogen and fibrin stabilizer].
    Buluk K; Zuch A
    Postepy Hig Med Dosw; 1968; 22(1):177-91. PubMed ID: 5665067
    [No Abstract]   [Full Text] [Related]  

  • 33. Fibrin degradation products. A review of structures found in vitro and in vivo.
    Gaffney PJ
    Ann N Y Acad Sci; 2001; 936():594-610. PubMed ID: 11460518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN; Kizim AI
    Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-dependent nature of the interaction of fibrinogen-degradation products and 5-hydroxytryptamine on various vascular smooth muscle preparations [proceedings].
    Forster C; Mohan J; Whalley ET
    Br J Pharmacol; 1980 Jan; 68(1):151P. PubMed ID: 7357163
    [No Abstract]   [Full Text] [Related]  

  • 36. [Effect of fibrinogen degradation products on the isolated rat uterus].
    Malofiejew M
    Ginekol Pol; 1967; 38(10):1167-73. PubMed ID: 4228957
    [No Abstract]   [Full Text] [Related]  

  • 37. Fibrinogen and fibrin degradation products and the clumping of staphylococci by serum.
    Allington MJ
    Br J Haematol; 1967 Jul; 13(4):550-67. PubMed ID: 6029955
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of histones and dextran on some properties of fibrin, particularly on its susceptibility to plasmin.
    Kppeć M; Wegrzynowicz Z; Zajdel M; Sawecka J; Szumiel I
    Thromb Res; 1974 Sep; 5(3):359-74. PubMed ID: 4280155
    [No Abstract]   [Full Text] [Related]  

  • 39. The action of plasmin on fibrin and fibrinogen in blood.
    MULLERTZ S
    Acta Physiol Scand; 1953 Mar; 28(1):29-40. PubMed ID: 13065148
    [No Abstract]   [Full Text] [Related]  

  • 40. Human platelet clumping by bovine fibrinogen during its degradation.
    De Gaetano G; Donati MB; Vermylen J
    Scand J Haematol Suppl; 1971; 13():281-3. PubMed ID: 4258203
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.